Be Agilent Sure and reliably identify the presence of aggregates in
characterization of mAbs
You have been chosen to receive this valuable information.
<http://www.chromatographyonline.com/>
  	
 
View this email in your browser
<http://creative.advanstar.com/lcgc/2018/Feb18/Agilent_1218/index.html>
or as plain text
<http://www.chem.agilent.com/edm/2017/12/molecular/pages/molecular-biopharma-edm.txt>
	Agilent Technologies

<http://www.agilent.com/>
  	 

For Aggregate Analysis | IN BIOPHARMA, THREE QUESTIONS ARE CRITICAL
<https://www.agilent.com/en/promotions/bioseparations>

  	  	 
  	

Reliably identify the presence of aggregates in characterization of mAbs

Monoclonal antibody (mAb) biotherapeutics have emerged as a critical
class of drugs. The efficacy and safety of these biotherapeutics are
highly dependent on maintaining a correct molecular structure. The
presence of aggregates can lead to undesirable consequences, such as
loss of therapeutic activity or even negative physiological effects.
Identifying the presence of aggregate proteins in biotherapeutics is
crucial.

Nobody understands better than Agilent

A unique non-destructive prescreening method using the Agilent Cary 60
UV-Vis spectrophotometer can quickly, easily, and reliably identify the
presence of aggregate proteins.

BE AGILENT SURE

  	Learn more

<https://www.agilent.com/en/promotions/bioseparations> 	 

	  	
Featured Webinar
<http://connect.acspubs.org/CENWebinar_Agilent_WebinarSeries_10_24_17?partnerref=CENonline>


Featured Webinar:
How fab are your mAbs?

A complete aggregate analysis workflow for comprehensive, efficient, and
reliable characterization of monoclonal antibodies

  	Register

<http://connect.acspubs.org/CENWebinar_Agilent_WebinarSeries_10_24_17?partnerref=CENonline>
	 

 

New Application Note <https://www.agilent.com/en/promotions/bioseparations>

New Application Note

Characterization of mAb Aggregation Using an
Agilent Cary 60 UV-Vis
and 1260 Infinity LC

  	Learn more

<https://www.agilent.com/en/promotions/bioseparations> 	 

	  	 
  	
CONNECT WITH AGILENT 	Facebook
<https://www.facebook.com/Agilent.Tech> 	  	Twitter
<http://twitter.com/agilent> 	  	LinkedIn
<https://www.linkedin.com/company/agilent-technologies> 	  	Youtube
<https://www.youtube.com/user/agilent> 	 

	 
  	  	 
  	Agilent Home <http://www.agilent.com/>  |  About Agilent
<http://www.agilent.com/about>  |  Legal
<http://www.agilent.com/go/terms>  |  Subscriptions
<http://www.agilent.com/en-us/newsletters>  |  5301 Stevens Creek Blvd,
Santa Clara CA 95051, USA

Agilent is committed to respecting and protecting your privacy. To view
the promises that we make to you regarding your personal information,
please view Agilent's privacy statement
<http://www.agilent.com/go/privacy>. For questions related to privacy,
please send your inquiry to privacy_advocate@agilent.com
<mailto:privacy_advocate@agilent.com>. If you prefer not to receive
promotional e-mails from Agilent in the future, you can unsubscribe
<http://www.agilent.com/cs/agilent/en-us/globaloptout/form> at any time.
You can also update
<http://www.agilent.com/en-us/contact-us/na-profileupdate> your e-mail
address, contact information, or interest profile to ensure you receive
the most relevant information.

&copy Agilent Technologies, Inc. 2018

	 
  	  	 

Message above is a paid advertisement. Content is provided by the
sponsor. You received this email because you are a customer of LCGC, a
UBM publication. You are on the mailing list as %%emailaddress%%
<file:///Users/51661766/Desktop/satya/2018/Feb/12/Agilent_1218/%%emailaddress%%>.